Jiangxi Synergy Pharmaceutical Co Ltd

Jiangxi Synergy Pharmaceutical Co Ltd maintains a debt-to-equity ratio of 0.27, indicating a relatively conservative capital structure with equity significantly outweighing liabilities. The company's liquidity position is assessed as medium, with a key flag noting that net cash is negative after subtracting total debt, suggesting potential short-term liquidity constraints. Profitability metrics for the company are not explicitly provided, but the operating cash flow of 202,070,740 CNY indicates positive cash generation from operations. However, the capital expenditure of -291,242,890 CNY suggests a significant outflow, potentially related to investments in long-term assets or restructuring activities. The company's revenue concentration and geographic exposure are not disclosed in the available data, limiting the ability to assess segment or regional risk. Without segment-specific revenue data, it is not possible to determine the extent of diversification or concentration in any particular product line or market. Looking ahead, the company's growth trajectory is not clearly defined in the available data. Analysts have provided a mean recommendation of 1.00, indicating a strong buy consensus, with one strong-buy rating and no buy, hold, sell, or strong-sell ratings. The mean EPS estimate of 0.32 CNY is higher than the last actual EPS of 0.17 CNY, suggesting potential earnings growth. The company's risk profile includes a low dilution risk, with no near-term pressure from dilution sources. However, the negative net cash position after subtracting total debt raises concerns about liquidity risk, particularly if the company faces unexpected cash outflows or reduced operating cash flow. Recent events, including filings and transcripts, are not detailed in the available data, limiting the ability to assess the company's recent strategic or operational developments.